Disclosed herein is a medical device for extended release of drugs. The device comprises a stent embedded with one or more drug depots that release of a therapeutic agent in a controlled manner. Each end of the stent may contain one or more anchors or attachment points which enable self-retention of the medical device once properly placed. The disclosed device further comprises a biosensor to monitor physiological characteristics like, e.g., intraocular pressure (IOP).

Described herein are medical devices and medical implements with high lubricity to flesh (or biological fluid) and/or inhibited nucleation on its surface. The device has a surface comprising an impregnating liquid and a plurality of micro-scale and/or nano-scale solid features spaced sufficiently close to stably contain the impregnating liquid therebetween. The impregnating liquid fills spaces between said solid features, the surface stably contains the impregnating liquid between the solid features, and the impregnating liquid is substantially held in place between the plurality of solid features regardless of orientation of the surface.

Injection systems comprising a powered injector and one or more hazardous agents are disclosed.

In some aspects, the invention relates to a porous implant, comprising a resorbable or bio-erodible porous silicon-based carrier material; a reservoir formed within the body of the porous silicon-based carrier material; and a beneficial substance disposed within the reservoir.

The present invention describes a composition in form of a gel for the virucidal disinfection of mammalian skin comprising 71 to 95 weight percent of a C1 to C3 monoalcohol, 0.01 to 1 weight percent thickener and wherein the composition has a viscosity range of from 3000 to 19000 mPas measured at 20 C. with spindle LV3 at a speed of 2.5 rpm. Furthermore, the invention describes a method for virucidal disinfection of skin.

Therapeutic bactericidal, antiviral, anti-inflammatory, antifungal, blood clotting, and regenerative compositions comprising thiazine dye and phosphoric acid

Injection systems comprising a powered injector and one or more hazardous agents are disclosed.

In various embodiments deformable nano-scale vehicles (DNV) are provided that are useful for the delivery of therapeutic agents. In certain embodiments the DNVs are capable of transdermal delivery and can additionally cross the blood-brain barrier.

A formulation for treating neurodegenerative diseases comprising a combination of rapamycin and metformin in a molar ratio of about 20:1, 10:1, 5:1, 4:1, 3:1, or 1:1. A method of treating neurodegenerative diseases comprising administering the formulation comprising a combination of rapamycin and metformin in a molar ratio of about 20:1, 10:1, 5:1, 4:1, 3:1, or 1:1.

Injection systems comprising a powered injector and one or more hazardous agents are disclosed.